secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K/A
Filed at:   2024-07-05T23:59:59+00:00
Accession:  0001477932-24-004096
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab Corp amends CEO/acting CFO compensation: base salary $35k/month effective July 1, 2024, plus back pay
--------------------------------------------------------------------------------

- Base salary for CEO/acting CFO Su-Leng Tan Lee set at $35,000 per month effective July 1, 2024.
- Company will recognize back pay at this rate from when Tan Lee began serving as CEO and CFO.
- Inducement Award Entitlement to be finalized by Compensation Committee in Q3 2024.
- Amendment approved by Compensation Committee on June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224004096/0001477932-24-004096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224004096/bglc_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-004096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer